Andere Sprachen Toleranzia AB

Aktien

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 14:28:17 13.05.2024			% 5 Tage	% 1. Jan.
0,536 ^SEK	-0,37 %		-4,29 %	+25,23 %

23.02.	Toleranzia AB meldet Ergebnis für das vierte Quartal bis zum 31. Dezember 2023	CI
23.02.	Toleranzia AB meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Toleranzia AB: Annual report for the financial year 2023	30.04.
Toleranzia AB receives loan commitment of SEK 20 million	24.04.
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program	18.03.
Toleranzia AB – Year-End Report 2023	23.02.
Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23.02.
Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023	23.02.
Toleranzia successfully completes GLP toxicology study of TOL2	15.01.
Toleranzia AB Successfully Completes GLP Toxicology Study of TOL2	15.01.
Toleranzia AB starts production of finished drug product for clinical studies	21.12.
Toleranzia AB Starts Production of Completed Drug Product for Clinical Studies	21.12.
Toleranzia AB presents Nomination Committee	15.12.
Toleranzia AB Announces Nomination Committee	15.12.
Toleranzia reports positive feedback from meeting with the Danish Medicines Agency	06.12.
Toleranzia AB: Interim report third quarter 2023	27.10.23
Toleranzia AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27.10.23
Toleranzia Appoints Successor to Outgoing CFO	16.10.23
Toleranzia appoints Thomas Pålsson as new Chief Financial Officer	16.10.23
Toleranzia AB Announces Executive Changes	16.10.23
Toleranzia starts toxicology study of its lead drug candidate TOL2	26.09.23
Toleranzia AB Starts Toxicology Study of its Lead Drug Candidate TOL2	26.09.23

Keine Ergebnisse zu dieser Suche